---
figid: PMC9139752__cancers-14-02353-g001
figtitle: Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging
  Agents?
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC9139752
filename: cancers-14-02353-g001.jpg
figlink: /pmc/articles/PMC9139752/figure/cancers-14-02353-f001/
number: F1
caption: Upon replication stress caused by various types of DDA, SLFN11-proficient
  cells undergo an enforced G1/S arrest ultimately resulting in cell death (B). On
  the contrary, SLFN11-deficient cells reliant on the ATR/CHK1 pathway re-enter the
  cell cycle, slowly progress through the S-phase, and following DNA repair can survive
  (A). SLFN11 expression can be reactivated by the inhibitors of epigenetic modulators,
  such as DNA methyltransferase (DNMT), histone deacetylase (HDAC), or EZH2 inhibitors.
  Resistance of SLFN11-deficient cells can be overcome by combination with ATR/CHK1/WEE1
  inhibitors.
papertitle: Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with
  DNA-Damaging Agents?.
reftext: Marketa Bednarikova, et al. Cancers (Basel). 2022 May;14(10):2353.
year: '2022'
doi: 10.3390/cancers14102353
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: SLFN11 | ovarian cancer | high-grade serous carcinoma | DNA-damaging agents
  | PARPi | chemoresistance
automl_pathway: 0.904196
figid_alias: PMC9139752__F1
figtype: Figure
redirect_from: /figures/PMC9139752__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9139752__cancers-14-02353-g001.html
  '@type': Dataset
  description: Upon replication stress caused by various types of DDA, SLFN11-proficient
    cells undergo an enforced G1/S arrest ultimately resulting in cell death (B).
    On the contrary, SLFN11-deficient cells reliant on the ATR/CHK1 pathway re-enter
    the cell cycle, slowly progress through the S-phase, and following DNA repair
    can survive (A). SLFN11 expression can be reactivated by the inhibitors of epigenetic
    modulators, such as DNA methyltransferase (DNMT), histone deacetylase (HDAC),
    or EZH2 inhibitors. Resistance of SLFN11-deficient cells can be overcome by combination
    with ATR/CHK1/WEE1 inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - CHEK1
  - THOP1
  - LINC00273
  - TOP1
  - TOP1MT
  - TOP3A
  - TOP3B
  - TOP2A
  - TOP2B
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - SLFN11
  - EZH2
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - DNMT1
  - DNMT3A
  - DNMT3B
  - DNMT3L
  - Atr
  - Mmab
  - Chek1
  - Parp1
  - .na.character
  - Ezh2
  - Dnmt1
  - mei-41
  - put
  - RYa-R
  - grp
  - CycE
  - cyc
  - Egfr
  - Parp
  - Low
  - E(z)
  - Mt2
  - Nmt
  - Wee1
---
